Table 2. Risk factors for CLNM in PTC.
| Intercept and variable | Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|---|
| β | Odds ratio (95% CI) | P | β | Odds ratio (95% CI) | P | ||
| Intercept | 1.525 | 0.006 | 1.445 | 0.019 | |||
| Sex | −0.823 | 0.439 (0.282 to 0.683) | <0.001 | −0.820 | 0.440 (0.283 to 0.685) | <0.001 | |
| Age | −0.028 | 0.603 (0.449 to 0.809) | <0.001 | −0.028 | 0.603 (0.449 to 0.809) | <0.001 | |
| Tumor size | 0.433 | 1.477 (1.199 to 1.819) | <0.001 | 0.435 | 1.480 (1.200 to 1.824) | <0.001 | |
| Multifocality | 0.960 | 2.613 (1.679 to 4.066) | <0.001 | 0.952 | 2.591 (1.659 to 4.048) | <0.001 | |
| US- based CLNM status | 1.084 | 2.957(1.859 to 4.703) | <0.001 | 1.093 | 2.982(1.868 to 4.762) | <0.001 | |
| Braf | NA | NA | NA | 0.085 | 1.088(0.614 to 1.930) | 0.772 | |
| C-index | |||||||
| Primary cohort | 0.765 (0.724 to 0.806) | 0.764 (0.723 to 0.805) | |||||
| Validation cohort | 0.791 (0.740 to 0.842) | 0.792 (0.741 to 0.843) | |||||
β is the regression coefficient. CI, confidence interval; NA, not available; PTC, papillary thyroid carcinoma; US, ultrasound; CLNM, central lymph node metastasis; NA, not applicable.